Dual Checkpoint Blockade Active in Rare Tumors

(MedPage Today) -- A fourth of patients with angiosarcoma had objective responses to the combination of low-dose ipilimumab (Yervoy) and nivolumab (Opdivo), according to a subgroup analysis of an ongoing study of rare cancers.
Four of 16 patients...